Therapeutic programs in development

Building a diversified pipeline of regenerative therapies powered by scalable and reproducible exosome biology.

Lead program

EVerGel

Complex perianal fistula

  1. Discovery
  2. PoC
  3. CTA enabling
  4. Phase 1/2a
  5. Phase 3

Localized exosome therapy for digestive tissue regeneration

EverGel is our lead therapeutic program targeting complex perianal fistula,
a significant unmet medical need in Crohn’s disease (inflammatory bowel disease).

Indication: Complex perianal fistula

A complex perianal fistula is an abnormal tract connecting the rectum to the skin outside the body. Despite available treatment options, complex perianal fistulas remain a significant unmet medical need and a main complication of Crohn disease.

A significant burden for Crohn’s disease patients

We focus on Crohn’s disease, a chronic inflammatory bowel disease in
which 40% of patients will develop a perianal fistula during their life time.
0
of Crohn patients fail
to permanently close their fistula
0
new
patient/year
0
patients
world wide

First-in-human studies in Crohn’s disease-associate

complex perianal fistula are planned for early 2027.

EVerGel is designed for localized regenerative activity

EVerGel combines stem cell-derived exosomes with a thermoresponsive hydrogel designed for local administration. The hydrogel enables controlled exosome release, improves retention at the site of injury, and fills irregular defects, including complex and difficult-to-access fistula tracts.

Demonstrated regenerative activity
in preclinical models

We focus on Crohn’s disease, a chronic inflammatory bowel disease in
which 40% of patients will develop a perianal fistula during their life time.

Model of gastro-cutaneous
post chirurgical fistula

Animals with closed fistula

Model of colocutaneous
fistula

Animals with closed fistula

See our publications